We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Donors Screened for Human Leukocyte Antigen Antibodies

By LabMedica International staff writers
Posted on 10 Jan 2011
Male blood donors have been screened by two serum tests to determine if they had antibodies to human leukocytes antigens (HLA), which may cause harm to the recipient. More...


The donor serum samples were initially screened for HLA class I and/or class II antibodies with a panel of fluorescent beads coated with HLA class I and class II antigen preparations using multiplex technology and an enzyme linked immunoassay-based method.

In a study carried out at the University of Texas (Houston, TX, USA), the fluorescent bead test (Luminex; Austin, TX, USA), confirmed that 33 donors were positive for HLA class I and/or II antibodies. The agreement rates between the methods for HLA class I and II antibodies were 21% (7/33) and 6% (2/33), respectively. The DonorScreen ELISA-based method, (GTI; Waukesha, WI, USA), was significantly more specific for HLA class I antibodies than for HLA class II antibodies. A false-positive result was reported for the HLA class I antibody in 2/33 (6%) of the donors and for the HLA class II antibody in 19/33 (58%) of the donors using the DonorScreen method.

A retrospective review of recipients of packed red blood cells (RBCs) and platelets processed from these 33 HLA-immunized male donors were conducted to identify transfusion-related acute lung injury (TRALI) and cognate antigens. HLA antibodies in the male donors corresponding to cognate antigens were found in two recipients of packed RBCs and in three recipients of platelets. Of eight donors positive for HLA antibodies, five did not have a history of blood transfusion.

Transfusion of virtually all blood products is implicated as a cause of TRALI, which can occurs within six hours of receipt of the product. In addition to infusion of packed RBCs, platelets, and fresh frozen plasma, transfusion of allogeneic stem cells and intravenous administration of immunoglobulin, and granulocytes have been implicated as causes of TRALI. The authors concluded that the ELISA method was too sensitive and had a high false-positive rate for the detection of HLA class II antibodies, and therefore excluding possible donors. The study was published in January 2011 in the American Journal of Clinical Pathology.

Related Links:

University of Texas
Luminex
GTI



New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.